Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial
Prica, A.; Hay, A.E.; Crump, M.; Mittmann, N.; Shepherd, L.E.; Meyer, R.M.; Imrie, K.I.; Risebrough, N.; Djurfeldt, M.; Chen, B.E.; Cheung, M.C. Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial. Curr. Oncol. 2021, 28, 1256-1261. https://doi.org/10.3390/curroncol28020119
Prica A, Hay AE, Crump M, Mittmann N, Shepherd LE, Meyer RM, Imrie KI, Risebrough N, Djurfeldt M, Chen BE, Cheung MC. Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial. Current Oncology. 2021; 28(2):1256-1261. https://doi.org/10.3390/curroncol28020119
Chicago/Turabian StylePrica, Anca; Hay, Annette E.; Crump, Michael; Mittmann, Nicole; Shepherd, Lois E.; Meyer, Ralph M.; Imrie, Kevin I.; Risebrough, Nancy; Djurfeldt, Marina; Chen, Bingshu E.; Cheung, Matthew C. 2021. "Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial" Curr. Oncol. 28, no. 2: 1256-1261. https://doi.org/10.3390/curroncol28020119